Treatment of patients with factor VIII and factor IX inhibitors with special focus on the use of recombinant factor VIIa.
Hedner
U
U
Department of Coagulation Disorders, University Hospital of Malmö, University of Lund, Sweden.
D000707:Anaphylaxis; D000818:Animals; D000906:Antibodies; D005164:Factor IX / Q000276:immunology / Q000627:therapeutic use*; D005169:Factor VIII / Q000276:immunology / Q000627:therapeutic use*; D015942:Factor VIIa / Q000276:immunology / Q000494:pharmacology / Q000627:therapeutic use*; D006467:Hemophilia A / Q000188:drug therapy* / Q000276:immunology; D002836:Hemophilia B / Q000188:drug therapy* / Q000276:immunology; D006801:Humans; D007108:Immune Tolerance; D007165:Immunosuppression Therapy; D011994:Recombinant Proteins / Q000627:therapeutic use
D000906:Antibodies; D011994:Recombinant Proteins; D005169:Factor VIII; D005164:Factor IX; D015942:Factor VIIa